Last reviewed · How we verify

NCT07176416

Effective Phaco Time and Endothelial Cell Loss When Using Veritas

Recruiting now Last updated 9 October 2025
What this trial tests

trial testing Veritas Vision System in Cataract in 50 participants. Currently enrolling.

Timeline
3 October 2025
Primary endpoint
1 October 2026
1 October 2026

Quick facts

Lead sponsorAloha Vision Consultants
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment50
Start date3 October 2025
Primary completion1 October 2026
Estimated completion1 October 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Aloha Vision Consultants

Who can join

Eligibility, any sex, with Cataract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single center, prospective study of cumulative dissipated energy and endothelial cells loss per phacoemulsification procedure after successful cataract surgery. Subjects will be assessed 3 months postoperatively at a single visit. Clinical evaluations will include central corneal thickness, specular microscopy, as well as measurement of visual acuities at distance.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cataract

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07176416.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing